See more : Citigroup Inc. (C-PK) Income Statement Analysis – Financial Results
Complete financial analysis of Genocea Biosciences, Inc. (GNCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genocea Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SunCoke Energy, Inc. (SXC) Income Statement Analysis – Financial Results
- Grindr Inc. WT (GRND-WT) Income Statement Analysis – Financial Results
- Taiwan Navigation Co., Ltd. (2617.TW) Income Statement Analysis – Financial Results
- Suli Co., Ltd. (603585.SS) Income Statement Analysis – Financial Results
- Domo, Inc. (DOMO) Income Statement Analysis – Financial Results
Genocea Biosciences, Inc. (GNCA)
About Genocea Biosciences, Inc.
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.64M | 1.36M | 0.00 | 0.00 | 0.00 | 235.00K | 670.00K | 308.00K | 731.00K | 1.98M | 1.82M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.64M | 1.36M | 0.00 | 0.00 | 0.00 | 235.00K | 670.00K | 308.00K | 731.00K | 1.98M | 1.82M |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.02M | 33.96M | 26.95M | 25.21M | 39.20M | 33.05M | 28.05M | 23.73M | 15.70M | 11.24M | 13.54M |
| General & Administrative | 14.71M | 14.39M | 12.04M | 14.31M | 13.43M | 15.43M | 13.99M | 9.75M | 4.96M | 3.69M | 3.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.39M | 12.04M | 14.31M | 13.43M | 15.43M | 13.99M | 9.75M | 4.96M | 3.69M | 3.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 2.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.73M | 48.35M | 38.99M | 39.52M | 52.64M | 48.48M | 42.04M | 33.47M | 20.66M | 14.93M | 16.55M |
| Cost & Expenses | 53.73M | 48.35M | 38.99M | 39.52M | 52.64M | 48.48M | 42.04M | 33.47M | 20.66M | 14.93M | 16.55M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 410.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.12M | 1.38M | 946.00K | 1.02M | 1.71M | 1.74M | 1.12M | 970.00K | 459.00K | 507.00K | 33.00K |
| Depreciation & Amortization | 17.78M | 1.14M | 1.10M | 1.09M | 1.52M | 1.81M | 1.05M | 469.00K | 318.00K | 300.00K | 318.00K |
| EBITDA | -34.32M | -41.20M | -36.91M | -25.70M | -53.49M | -46.02M | -40.32M | -33.86M | -20.03M | -12.56M | -14.33M |
| EBITDA Ratio | -2,091.22% | -3,031.35% | 0.00% | 0.00% | 0.00% | -19,583.83% | -6,017.16% | -10,992.53% | -2,739.95% | -635.31% | -787.58% |
| Operating Income | -52.09M | -46.99M | -38.99M | -39.52M | -55.26M | -48.25M | -41.37M | -33.17M | -19.93M | -12.95M | -14.73M |
| Operating Income Ratio | -3,174.47% | -3,457.62% | 0.00% | 0.00% | 0.00% | -20,529.79% | -6,174.03% | -10,768.18% | -2,725.72% | -655.18% | -809.18% |
| Total Other Income/Expenses | 18.90M | 3.28M | 39.00K | 11.71M | -1.46M | -1.33M | -1.12M | -2.13M | -881.00K | -414.00K | 42.00K |
| Income Before Tax | -33.20M | -43.71M | -38.95M | -27.81M | -56.71M | -49.57M | -42.48M | -35.30M | -20.81M | -13.37M | -14.69M |
| Income Before Tax Ratio | -2,022.91% | -3,216.63% | 0.00% | 0.00% | 0.00% | -21,094.89% | -6,340.75% | -11,459.74% | -2,846.24% | -676.13% | -806.87% |
| Income Tax Expense | -17.78M | 4.66M | 985.00K | 12.73M | 250.00K | 410.00K | 0.00 | -1.16M | -422.00K | 93.00K | 75.00K |
| Net Income | -15.42M | -43.71M | -38.95M | -27.81M | -56.71M | -49.57M | -42.48M | -35.30M | -20.81M | -13.37M | -14.69M |
| Net Income Ratio | -939.67% | -3,216.63% | 0.00% | 0.00% | 0.00% | -21,094.89% | -6,340.75% | -11,459.74% | -2,846.24% | -676.13% | -806.87% |
| EPS | -0.22 | -0.94 | -1.89 | -2.69 | -15.86 | -14.01 | -13.89 | -18.08 | -9.67 | -14.31 | -11.68 |
| EPS Diluted | -0.22 | -0.94 | -1.89 | -2.69 | -15.86 | -14.01 | -13.89 | -18.08 | -9.67 | -14.31 | -11.68 |
| Weighted Avg Shares Out | 68.58M | 46.55M | 20.64M | 10.32M | 3.58M | 3.54M | 3.06M | 1.95M | 2.15M | 934.00K | 1.26M |
| Weighted Avg Shares Out (Dil) | 68.58M | 46.55M | 20.64M | 10.32M | 3.58M | 3.54M | 3.06M | 1.95M | 2.15M | 934.00K | 1.26M |
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the.
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer...
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10t...
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual...
Genocea to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021...
Source: https://incomestatements.info
Category: Stock Reports